The event will be co-hosted by Dr Sarah Payne, Product Manager at TTP LabTech Ltd and Dr Michael Howell, Head of the High Throughput Screening Facility at Cancer Research UK’s London Research Institute.
Following an introduction to the key features of the Acumen eX3 that have led to its global adoption by researchers in high throughput screening departments, Dr Michael Howell will outline the involvement of Cancer Research UK in two on-going functional genome-wide siRNA projects. The first screening project investigates the molecular mechanisms of PKC-induced activation of ADAM proteases by measuring ectodomain shedding of a HB-EGF fusion protein. The second functional screen aims to determine genomic instability, survival, and drug resistance pathways in human cancer by measuring changes in ploidy, cell survival, and apoptosis with a view to establishing more effective combinatorial therapy regimes.
To find out more information about TTP LabTech’s presence at the RNAi Europe 2009 conference please visit www.ttplabtech.com/events/